Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts

Cardiol Therapeutics Inc. (NASDAQ:CRDL) has been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.40.

CRDL has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Monday. Rodman & Renshaw assumed coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price for the company. Finally, RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Tejara Capital Ltd raised its stake in shares of Cardiol Therapeutics by 75.9% in the 4th quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company’s stock valued at $3,988,000 after purchasing an additional 1,344,167 shares during the period. PVG Asset Management Corp bought a new position in Cardiol Therapeutics in the fourth quarter valued at $624,000. Envestnet Asset Management Inc. acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at $398,000. Lion Street Advisors LLC lifted its position in Cardiol Therapeutics by 12.6% during the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock worth $396,000 after buying an additional 34,385 shares in the last quarter. Finally, Foundations Investment Advisors LLC boosted its position in Cardiol Therapeutics by 237.4% during the third quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock valued at $321,000 after purchasing an additional 113,950 shares during the last quarter. Institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics Trading Down 2.5 %

CRDL opened at $1.17 on Friday. The firm has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $1.68. Cardiol Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $3.12. The company has a market cap of $96.65 million, a price-to-earnings ratio of -3.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.